Publication Date
| In 2026 | 0 |
| Since 2025 | 0 |
| Since 2022 (last 5 years) | 0 |
| Since 2017 (last 10 years) | 0 |
| Since 2007 (last 20 years) | 2 |
Descriptor
| Autism | 2 |
| Behavior Change | 2 |
| Drug Therapy | 2 |
| Outcomes of Treatment | 2 |
| Symptoms (Individual… | 2 |
| Adolescents | 1 |
| Adults | 1 |
| Behavior Problems | 1 |
| Check Lists | 1 |
| Children | 1 |
| Control Groups | 1 |
| More ▼ | |
Source
| Journal of Autism and… | 2 |
Author
| Aman, Michael | 1 |
| Fung, Lawrence K. | 1 |
| Haddad, Francois | 1 |
| Hardan, Antonio Y. | 1 |
| Hough, David | 1 |
| Karcher, Keith | 1 |
| Kent, Justine M. | 1 |
| Kushner, Stuart | 1 |
| Libove, Robin A. | 1 |
| Ness, Seth | 1 |
| Ning, Xiaoping | 1 |
| More ▼ | |
Publication Type
| Journal Articles | 2 |
| Reports - Research | 2 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
| Aberrant Behavior Checklist | 2 |
| Obsessive Compulsive Scale | 1 |
What Works Clearinghouse Rating
Fung, Lawrence K.; Libove, Robin A.; Phillips, Jennifer; Haddad, Francois; Hardan, Antonio Y. – Journal of Autism and Developmental Disorders, 2014
The objective of this study was to assess the tolerability and efficacy of pregnenolone in reducing irritability in adults with autism spectrum disorder (ASD). This was a pilot, open-label, 12-week trial that included twelve subjects with a mean age of 22.5 ± 5.8 years. Two participants dropped out of the study due to reasons unrelated to adverse…
Descriptors: Adults, Pervasive Developmental Disorders, Autism, Drug Therapy
Kent, Justine M.; Kushner, Stuart; Ning, Xiaoping; Karcher, Keith; Ness, Seth; Aman, Michael; Singh, Jaskaran; Hough, David – Journal of Autism and Developmental Disorders, 2013
Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients (N = 96; 5-17 years), received risperidone (low-dose: 0.125 mg/day [20 to <45 kg], 0.175 mg/day [>45 kg] or high-dose: 1.25 mg/day [20 to <45 kg], 1.75 mg/day [>45 kg]) or placebo. Mean baseline (range 27-29) to endpoint change…
Descriptors: Drug Therapy, Children, Adolescents, Autism

Peer reviewed
Direct link
